Long-term natural history of idiopathic epiretinal membranes with good visual acuity.


Journal

Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986

Informations de publication

Date de publication:
05 2019
Historique:
received: 12 06 2018
accepted: 24 11 2018
revised: 08 11 2018
pubmed: 20 4 2019
medline: 23 5 2020
entrez: 20 4 2019
Statut: ppublish

Résumé

To evaluate the long-term progression of idiopathic epiretinal membranes (iERMs) with good baseline visual acuity, and to identify predictors of visual decline. Retrospective case series SUBJECTS METHODS: We reviewed records of 145 eyes with iERM and best-corrected visual acuity (BCVA) of 20/40 or greater at presentation, including BCVA, lens status, and central macular thickness (CMT) at yearly visits; as well as anatomic biomarkers including vitreomacular adhesion, pseudohole, lamellar hole, intraretinal cysts, disorganization of the inner retinal layers (DRIL), and disruption of outer retinal layers. Linear mixed effects and mixed-effects Cox proportional hazards models were used to identify clinical and anatomic predictors of vision change and time to surgery. At presentation, mean BCVA was 0.17 ± 0.10 logMAR units (Snellen 20/30) and mean CMT was 353.3 ± 75.4 μm. After a median follow-up of 3.7 years (range 1-7 years), BCVA declined slowly at 0.012 ± 0.003 logMAR units/year, with phakic eyes declining more rapidly than pseudophakic eyes (0.019 ± 0.003 vs. 0.010 ± 0.004 logMAR units/year). Metamorphopsia, phakic lens status, lamellar hole, and inner nuclear layer cysts were associated with faster visual decline. Cumulative rates of progression to surgery were 2.9, 5.6, 12.2, and 21.1% at years 1-4. Visual symptoms, metamorphopsia, greater CMT, and disruption of outer retinal layers were associated with greater hazard for surgery. Eyes with iERM and visual acuity ≥ 20/40 experience slow visual decline, with 21% of eyes requiring surgery after 4 years. Clinical and anatomic predictors of vision loss may be distinct from factors associated with earlier surgical intervention.

Sections du résumé

BACKGROUND/OBJECTIVES
To evaluate the long-term progression of idiopathic epiretinal membranes (iERMs) with good baseline visual acuity, and to identify predictors of visual decline.
DESIGN
Retrospective case series SUBJECTS METHODS: We reviewed records of 145 eyes with iERM and best-corrected visual acuity (BCVA) of 20/40 or greater at presentation, including BCVA, lens status, and central macular thickness (CMT) at yearly visits; as well as anatomic biomarkers including vitreomacular adhesion, pseudohole, lamellar hole, intraretinal cysts, disorganization of the inner retinal layers (DRIL), and disruption of outer retinal layers. Linear mixed effects and mixed-effects Cox proportional hazards models were used to identify clinical and anatomic predictors of vision change and time to surgery.
RESULTS
At presentation, mean BCVA was 0.17 ± 0.10 logMAR units (Snellen 20/30) and mean CMT was 353.3 ± 75.4 μm. After a median follow-up of 3.7 years (range 1-7 years), BCVA declined slowly at 0.012 ± 0.003 logMAR units/year, with phakic eyes declining more rapidly than pseudophakic eyes (0.019 ± 0.003 vs. 0.010 ± 0.004 logMAR units/year). Metamorphopsia, phakic lens status, lamellar hole, and inner nuclear layer cysts were associated with faster visual decline. Cumulative rates of progression to surgery were 2.9, 5.6, 12.2, and 21.1% at years 1-4. Visual symptoms, metamorphopsia, greater CMT, and disruption of outer retinal layers were associated with greater hazard for surgery.
CONCLUSION
Eyes with iERM and visual acuity ≥ 20/40 experience slow visual decline, with 21% of eyes requiring surgery after 4 years. Clinical and anatomic predictors of vision loss may be distinct from factors associated with earlier surgical intervention.

Identifiants

pubmed: 31000833
doi: 10.1038/s41433-019-0397-z
pii: 10.1038/s41433-019-0397-z
pmc: PMC6707144
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

714-723

Subventions

Organisme : NEI NIH HHS
ID : K08 EY026101
Pays : United States
Organisme : NEI NIH HHS
ID : K08 EY027463
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001860
Pays : United States

Références

Eye (Lond). 2014 Apr;28(4):410-4
pubmed: 24406414
Ophthalmology. 2003 Jan;110(1):34-40
pubmed: 12511343
Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2681-8
pubmed: 23680863
Am J Ophthalmol. 2000 Nov;130(5):677-9
pubmed: 11078854
Graefes Arch Clin Exp Ophthalmol. 2015 Jan;253(1):47-56
pubmed: 24859385
Retina. 2009 Sep;29(8):1119-27
pubmed: 19734764
Exp Eye Res. 2018 Mar;168:69-76
pubmed: 29352993
Am J Ophthalmol. 1999 Jun;127(6):688-93
pubmed: 10372879
Ophthalmologica. 2015;234(2):91-100
pubmed: 26302864
Diabetes. 2015 Jul;64(7):2560-70
pubmed: 25633419
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017 Mar;161(1):100-106
pubmed: 28096551
Invest Ophthalmol Vis Sci. 2011 Mar 18;52(3):1486-92
pubmed: 21071737
Curr Eye Res. 2016 Oct;41(10):1387-1392
pubmed: 26862944
Am J Ophthalmol. 2018 Apr;188:29-40
pubmed: 29360459
Ophthalmology. 2013 Dec;120(12):2611-2619
pubmed: 24053995
Graefes Arch Clin Exp Ophthalmol. 2007 Nov;245(11):1623-31
pubmed: 17479277
Ophthalmology. 2014 Aug;121(8):1572-8
pubmed: 24755005
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):4129-34
pubmed: 26114491
Eye (Lond). 2011 Jun;25(6):775-83
pubmed: 21436847
Invest Ophthalmol Vis Sci. 2012 Dec 07;53(13):8042-8
pubmed: 23111607
Am J Ophthalmol. 2004 Nov;138(5):732-9
pubmed: 15531306
Retina. 2014 Dec;34(12):2317-35
pubmed: 25360790
JAMA Ophthalmol. 2014 Nov;132(11):1309-16
pubmed: 25058813
Retina. 2000;20(6):587-90
pubmed: 11131409
JAMA Ophthalmol. 2018 Feb 1;136(2):202-208
pubmed: 29327033
Am J Ophthalmol. 2017 May;177:116-125
pubmed: 28237411
Am J Ophthalmol. 2012 Apr;153(4):710-7, 717.e1
pubmed: 22137207
Br J Ophthalmol. 2016 May;100(5):688-92
pubmed: 26377411
Am J Ophthalmol. 2011 Jun;151(6):973-80
pubmed: 21457925
Ophthalmology. 2013 Sep;120(9):1860-70
pubmed: 23642377

Auteurs

Kieu-Yen Luu (KY)

Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA.

Tynisha Koenigsaecker (T)

Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA.

Amirfarbod Yazdanyar (A)

Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA.

Lekha Mukkamala (L)

Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA.

Blythe P Durbin-Johnson (BP)

Department of Public Health Sciences, University of California, Davis, Sacramento, CA, USA.

Lawrence S Morse (LS)

Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA.

Ala Moshiri (A)

Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA.

Susanna S Park (SS)

Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA.

Glenn Yiu (G)

Department of Ophthalmology & Vision Sciences, University of California, Davis, Sacramento, CA, USA. gyiu@ucdavis.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH